SciCann Therapeutics
Cannabis and Cannabinoid Pharmaceuticals
Company Overview
Snapshot
Founded in June 2017 by Zohar Koren, PhD and Sheldon Inentash, SciCann Therapeutics operates with 1–10 employees. The company has raised $3 million across one funding round from FSD Pharma. In October 2019, SciCann Therapeutics received a notice of allowance for its enhanced CBD therapy US patent for NASH.
Business overview
SciCann Therapeutics is a Canadian-Israeli pharmaceutical company focused on developing and commercializing pharmaceutical products that target and modulate the endocannabinoid system. The company's core technology involves new therapeutic agents, drug candidates, novel cannabis genetics, and personalized treatment tools. SciCann Therapeutics operates in the fields of oncology, pain management, neurodegenerative diseases, and inflammatory disorders, developing proprietary products for life-threatening conditions with high unmet needs. It maintains a diversified intellectual property portfolio and collaborations with research institutes and commercial companies in the medical cannabis sector.
Strategic signal
In October 2019, SciCann Therapeutics received a notice of allowance for its enhanced CBD therapy US patent for NASH. This milestone indicates progress in the company's intellectual property development and validates its research into cannabinoid-based treatments for specific medical conditions, signaling potential for future product commercialization in the pharmaceutical market.
Log in to access full profile ›Company Intelligence Q&A
- What is SciCann Therapeutics' primary focus?
- SciCann Therapeutics is a pharmaceutical company that develops and commercializes products targeting and modulating the endocannabinoid system, including therapeutic agents, drug candidates, and novel cannabis genetics.
- When was SciCann Therapeutics founded and by whom?
- SciCann Therapeutics was founded in June 2017 by Zohar Koren, PhD and Sheldon Inentash.
- What was a significant intellectual property milestone for SciCann Therapeutics?
- In October 2019, SciCann Therapeutics received a notice of allowance for its enhanced CBD therapy US patent for NASH.
- What research collaboration did SciCann Therapeutics launch in September 2018?
- In September 2018, FSD Pharma and SciCann Therapeutics launched a cardiovascular research program at Tel Aviv University.
- What was the status of SciCann Therapeutics' "Steady Stomach" CBD combination therapy patent in November 2018?
- In November 2018, SciCann Therapeutics announced a positive ISA Report for its "Steady Stomach" CBD Combination Therapy Patent.